RBC Capital Reiterates Outperform on IDEAYA Biosciences, Maintains $45 Price Target

Benzinga · 2d ago
RBC Capital analyst Leonid Timashev reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $45 price target.